Announces Flotation on the O-list of the Stockholm Exchange

Announces Flotation on the O-list of the Stockholm Exchange Lund, Sweden: BioInvent International AB, the privately held Swedish antibody company, today announces that its Board of Directors has decided to expand the ownership structure of the company and to list the shares on the O-list of the Stockholm Exchange. The offering will encompass a maximum of 6,000,000 shares in the form of 4,500,000 newly issued shares and 1,500,000 existing shares owned by some of the company's current shareholders. Through the new share issue BioInvent will receive between SEK 270 million (US $ 26 million) and SEK 338 million (US $ 33 million) before deduction of transaction costs. The proceeds from the issue will, together with existing cash, be used to pursue product development in the area of protein arrays and for the development of proprietary therapeutic antibodies as well as for current operations. Key terms and conditions: · Price per share SEK 60 - 75 (US $ 5.9 - 7.4) · Application period May 21 - June 6, 2001 · Expected to be floated on the O-list of Stockholm Exchange on June 12, 2001 The offering is divided into an offering to institutional investors in Sweden and abroad and an offering to the general public in Sweden. The price for the shares in the offering will be set in a book-building procedure for the institutional offering and is expected to be set at between SEK 60 - 75 (US $ 5.9 - 7.4) per share. The selling price for the general public will not exceed SEK 75 (US $ 7.4) per share. After the new share issue, and assuming that all the options that mature in connection with the listing are utilised, the number of shares will amount to 28,144,305 shares, each with a nominal value of SEK 0.50. The shares offered will constitute 21.3 per cent of the company's capital after the new share issue and assuming full utilisation of options that mature in connection with the listing. As of Friday May 18, 2001 a prospectus may be ordered from D. Carnegie AB by telephone +46 (0)8-5886 9482 or from BioInvent International AB's website (www.bioinvent.com) or from D. Carnegie AB's website (www.carnegie.se/online). D. Carnegie AB is acting as Sole Lead Manager and Bookrunner in conjunction with the new share issue and the flotation. More information: BioInvent International AB Svein Mathisen President and Chief Executive Officer Telephone: +46 (0)46 286 85 67 Mobile: +46 (0)708 97 82 13 E-mail: sm@bioinvent.com Buchanan Communications Nicola How / Edward Cowdery Telephone: +44 (0)20 7466 5000 BioInvent International AB is a privately held biotechnology company devoted to providing state-of-the-art antibody technology to the pharmaceutical and biotech industry. A cornerstone is its proprietary human antibody gene library, n-CoDeRTM . This is a collection of more than ten billion functional antibody genes which are ready to be screened against desired antigens. n-CoDeRTM has been used successfully for the isolation of antibody fragments with specificity for a number of antigens, including peptides, proteins and carbohydrates. BioInvent offers biotechnology and pharmaceutical companies access to n-CoDeRTM through collaborative research and development programs. BioInvent's capabilities in large scale contract manufacturing of protein based drugs through a state-of-the-art cGMP - certified facility further underpins its competitiveness on the antibody arena. BioInvent has been supplying monoclonal antibodies, fusion proteins and other recombinant proteins to the world's leading pharmaceutical and biotechnology companies for therapeutic use since 1988. These antibodies and proteins are used in all phases of clinical trials in both the US and across Europe. The cGMP-certified production facility is designed to meet FDA and EU regulations from early clinical development to commercial scale-up, with multi-kilogram annual capacity. BioInvent is headquartered in Lund, Sweden, employing a total 100 people. Visit our website www.bioinvent.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00820/wkr0001.doc http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00820/wkr0002.pdf